Quantcast

Contract Research Organization WCCT Global Announces Strong Focus on Early and Late Phase Ophthalmology Clinical Research

July 25, 2013

WCCT Global has built a cutting edge center of excellence for ophthalmology clinical research over the past 5 years.

Costa Mesa, California (PRWEB) July 25, 2013

WCCT Global, a contract research organization announced they have implemented a strong focus on early and late phase Ophthalmology clinical research. This new capability stems from WCCT Global being a leader in both early and late stage drug development for ocular hypertension and glaucoma for several years. WCCT Global has now established an ophthalmology center of excellence which includes more than 12 leading Ophthalmology Investigator Sites. These highly skilled and experienced Investigators/Clinicians are available to collaborate with sponsors to offer strategies to more rapidly demonstrate local and systemic tolerance, proof of concept and ultimately, safety and efficacy for many ophthalmologic indications. Therefore, WCCT Global can now work with sponsors to design and execute clinical studies to meet the needs of the ophthalmologic product innovator or developer from first-in-man through Phase IV. Dr. Mel Affrime, Sr. VP, Translational Medicine at WCCT Global said, “We have been steadily building this unique capability over the past five years and it gives us great satisfaction to be able to participate in the development of cutting edge treatments that may slow or even reverse the visual impairment that is caused by many eye disorders.”.

Another key aspect to this announcement is WCCT Global has established a nation-wide patient network of diverse ethnicity backgrounds which is necessary to launch a Global Development Program months ahead of the classic separate geographic development paradigms. This strategy provides the sponsor organization, a significant strategic advantage over the competition. In addition to the network, WCCT Global is located in a densely populated and ethnically diverse location which enables a wide variety of subjects available for local study participation.

More about WCCT Global:

WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting-edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like more information about WCCT Global’s Glaucoma capabilities, CLICK HERE.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10960682.htm


Source: prweb



comments powered by Disqus